Background: Epinephrine autoinjector (EAI) is prescribed to prevent a fatal outcome in the case of a repeated anaphylactic reactions. We wanted to determine how adult patients who received their first prescription as part of an urgent treatment of an anaphylactic reaction or at their family physician were instructed on the use of EAI. Methods: Nurses assessing patients’ knowledge asked the patient to demonstrate how to use the EAI training device. Patients who performed the critical steps correctly in 1 min were labelled as competent. Results: Forty-one patients (24% women, 46 ± 5 years) came for the allergy examination 116 ± 145 days after receiving a prescription for EAI. When prescribing, the doctor or nurse explained the instructions for the use of EAI to 63.4% patients, and 31.7 patients practiced the use of EAI using a training device. At the pharmacy, 22% received explanation and 7% also practiced using a training device. Fifty-four percent of patients were able to effectively administer EAI adrenaline within 1 min. Higher education level was associated with sufficient knowledge about the use of EAI (p = 0.026). At the time of the visit to the allergy specialist clinic, 61% of patients had EAI with them. The shelf life of EAI was known to 63% of patients. Conclusions: The activities to increase the prescription rate of EAI immediately after treatment of anaphylactic episode are not sufficient to prevent severe outcome after the repeated episodes of anaphylaxis as nearly a half of patients are not able to use EAI correctly.
Int Arch Allergy Immunol

中文翻译：

---

在过敏反应后立即接受处方的患者中使用肾上腺素自动注射器的能力

背景：肾上腺素自动注射器 (EAI) 用于预防反复出现过敏反应的致命结果。我们想确定作为过敏反应紧急治疗的一部分或在他们的家庭医生处接受第一次处方的成年患者如何被指导使用 EAI。方法：评估患者知识的护士要求患者演示如何使用 EAI 培训设备。在 1 分钟内正确执行关键步骤的患者被标记为有能力。结果：41 名患者（24% 女性，46 ± 5 岁）在接受 EAI 处方后 116 ± 145 天进行过敏检查。处方时，医生或护士向63.4%的患者解释了EAI的使用说明，31.7名患者通过训练设备练习了EAI的使用。在药房，22% 的人接受了解释，7% 的人还使用训练设备进行了练习。54% 的患者能够在 1 分钟内有效地使用 EAI 肾上腺素。高等教育水平与有关 EAI 使用的足够知识相关（p = 0.026）。在访问过敏专科诊所时，61% 的患者患有 EAI。63% 的患者知道 EAI 的保质期。结论：在过敏性发作治疗后立即增加 EAI 处方率的活动不足以预防过敏性反应反复发作后的严重后果，因为近一半的患者无法正确使用 EAI。
Int Arch 过敏免疫